Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1986-10-21
pubmed:abstractText
A variety of clinical anaerobic isolates were tested against cefoperazone (216 strains), cefoxitin (120 strains), and cefotaxime (120 strains) by the thioglycolate anaerobic broth disk method, and the results were compared with the National Committee for Clinical Laboratory Standards reference agar dilution method. The broth disk and reference breakpoint concentrations were as follows: cefoperazone, 60 and 64 or 30 and 32 micrograms/ml; cefotaxime, 30 and 32 micrograms/ml; cefoxitin, 18 and 16 micrograms/ml, respectively. Discrepant results were retested to obtain a mode. There was 99% agreement between the broth disk and reference methods for cefotaxime, 98% for cefoperazone with 60- and 64-micrograms/ml breakpoints and 91% with 30- and 32-micrograms/ml breakpoints, and 75% for cefoxitin. All but one of the strains that produced false susceptibility results by broth disk were members of the Bacteroides fragilis group, 1 with cefoperazone using the 60-micrograms/ml concentration, 14 with cefoperazone at the 30-micrograms/ml concentration, and 27 with cefoxitin. One strain of Clostridium difficile produced false susceptibility results to cefoperazone at the 30-micrograms/ml concentration. The lack of agreement between the broth disk and reference methods with cefoxitin may be a reflection of the number of isolates at the 16-micrograms/ml level and that the broth disk breakpoint was slightly higher than this concentration. Increased incubation time did not improve the results significantly.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/3745418-1008552, http://linkedlifedata.com/resource/pubmed/commentcorrection/3745418-1137383, http://linkedlifedata.com/resource/pubmed/commentcorrection/3745418-1147597, http://linkedlifedata.com/resource/pubmed/commentcorrection/3745418-3514661, http://linkedlifedata.com/resource/pubmed/commentcorrection/3745418-400819, http://linkedlifedata.com/resource/pubmed/commentcorrection/3745418-464560, http://linkedlifedata.com/resource/pubmed/commentcorrection/3745418-4790586, http://linkedlifedata.com/resource/pubmed/commentcorrection/3745418-4790595, http://linkedlifedata.com/resource/pubmed/commentcorrection/3745418-6372033, http://linkedlifedata.com/resource/pubmed/commentcorrection/3745418-6447475, http://linkedlifedata.com/resource/pubmed/commentcorrection/3745418-6486758, http://linkedlifedata.com/resource/pubmed/commentcorrection/3745418-6595259, http://linkedlifedata.com/resource/pubmed/commentcorrection/3745418-6660860, http://linkedlifedata.com/resource/pubmed/commentcorrection/3745418-6718938, http://linkedlifedata.com/resource/pubmed/commentcorrection/3745418-7181473, http://linkedlifedata.com/resource/pubmed/commentcorrection/3745418-7387149, http://linkedlifedata.com/resource/pubmed/commentcorrection/3745418-7396458, http://linkedlifedata.com/resource/pubmed/commentcorrection/3745418-984807
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0095-1137
pubmed:author
pubmed:issnType
Print
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
181-5
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1986
pubmed:articleTitle
Predicting the susceptibility of anaerobes to cefoperazone, cefotaxime, and cefoxitin with the thioglycolate broth disk procedure.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't